Cantor Fitzgerald analyst Rick Bienkowski reiterated a Hold rating on Verve Therapeutics (VERV – Research Report) yesterday and set a price target of $22.00. The company’s shares closed yesterday at $12.82.
According to TipRanks, Bienkowski is an analyst with an average return of -27.7% and an 11.11% success rate. Bienkowski covers the Healthcare sector, focusing on stocks such as Editas Medicine, Intellia Therapeutics, and Beam Therapeutics.
Verve Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $39.38, representing a 207.18% upside. In a report released on August 14, J.P. Morgan also maintained a Hold rating on the stock with a $32.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $41.96 and a one-year low of $12.85. Currently, Verve Therapeutics has an average volume of 623.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
- Verve Therapeutics price target lowered to $55 from $56 at Guggenheim
- Verve Therapeutics reports Q2 EPS (87c), consensus (92c)
- Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
- Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
- Cathie Wood’s ARK Investment bought 96.3K shares of Verve Therapeutics today
